MiNK Therapeutics Reports Durable Responses with Allo-iNKT Cell Therapy agenT-797 in Refractory Solid Tumors

Reuters11-07

MiNK <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Durable Responses with Allo-iNKT Cell Therapy agenT-797 in Refractory Solid Tumors

MiNK Therapeutics Inc. has announced updated clinical results from a study evaluating its allogeneic invariant natural killer T (allo-iNKT) cell therapy, agenT-797, both as a monotherapy and in combination with anti-PD-1 therapy. The data, presented at the Society for Immunotherapy of Cancer $(SITC)$ Annual Meeting 2025, involved patients with advanced solid tumors that were refractory to all approved treatments, including checkpoint inhibitors. The results demonstrated durable survival, deep and lasting responses, and evidence of immune reactivation, with a reported median overall survival of approximately 23 months when agenT-797 was combined with anti-PD-1 therapy. The therapy showed a favorable safety profile and consistent activity across tumor types, supporting the potential of iNKT cells as a new class of immune-restorative therapy. MiNK Therapeutics plans to advance agenT-797 into Phase 2 studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571081-en) on November 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581886589?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581886589","market":"fut","top_or_hot":-1,"title":"MiNK Therapeutics Reports Durable Responses with Allo-iNKT Cell Therapy agenT-797 in Refractory Solid Tumors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MiNK <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Durable Responses with Allo-iNKT Cell Therapy agenT-797 in Refractory Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MiNK Therapeutics Inc. has announced updated clinical results from a study evaluating its allogeneic invariant natural killer T (allo-iNKT) cell therapy, agenT-797, both as a monotherapy and in combination with anti-PD-1 therapy. The data, presented at the Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> Annual Meeting 2025, involved patients with advanced solid tumors that were refractory to all approved treatments, including checkpoint inhibitors. The results demonstrated durable survival, deep and lasting responses, and evidence of immune reactivation, with a reported median overall survival of approximately 23 months when agenT-797 was combined with anti-PD-1 therapy. The therapy showed a favorable safety profile and consistent activity across tumor types, supporting the potential of iNKT cells as a new class of immune-restorative therapy. MiNK Therapeutics plans to advance agenT-797 into Phase 2 studies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571081-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MiNK Therapeutics Reports Durable Responses with Allo-iNKT Cell Therapy agenT-797 in Refractory Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMiNK Therapeutics Reports Durable Responses with Allo-iNKT Cell Therapy agenT-797 in Refractory Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MiNK <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Durable Responses with Allo-iNKT Cell Therapy agenT-797 in Refractory Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MiNK Therapeutics Inc. has announced updated clinical results from a study evaluating its allogeneic invariant natural killer T (allo-iNKT) cell therapy, agenT-797, both as a monotherapy and in combination with anti-PD-1 therapy. The data, presented at the Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> Annual Meeting 2025, involved patients with advanced solid tumors that were refractory to all approved treatments, including checkpoint inhibitors. The results demonstrated durable survival, deep and lasting responses, and evidence of immune reactivation, with a reported median overall survival of approximately 23 months when agenT-797 was combined with anti-PD-1 therapy. The therapy showed a favorable safety profile and consistent activity across tumor types, supporting the potential of iNKT cells as a new class of immune-restorative therapy. MiNK Therapeutics plans to advance agenT-797 into Phase 2 studies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571081-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL5Zs459:1","article_id":"2581886589","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581886589","pubTimestamp":1762524048,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MiNK Therapeutics Inc. has announced updated clinical results from a study evaluating its allogeneic invariant natural killer T  cell therapy, agenT-797, both as a monotherapy and in combination with anti-PD-1 therapy. The data, presented at the Society for Immunotherapy of Cancer  Annual Meeting 2025, involved patients with advanced solid tumors that were refractory to all approved treatments, including checkpoint inhibitors. The results demonstrated durable survival, deep and lasting responses, and evidence of immune reactivation, with a reported median overall survival of approximately 23 months when agenT-797 was combined with anti-PD-1 therapy. The therapy showed a favorable safety profile and consistent activity across tumor types, supporting the potential of iNKT cells as a new class of immune-restorative therapy. MiNK Therapeutics plans to advance agenT-797 into Phase 2 studies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intellige","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","INKT":"MiNK Therapeutics, Inc.","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所"},"translate_title":"MiNK Therapeutics报告Allo-iNKT细胞治疗剂-797在难治性实体瘤中的持久反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"INKT":0.9},"content_text":"MiNK Therapeutics Reports Durable Responses with Allo-iNKT Cell Therapy agenT-797 in Refractory Solid Tumors\n    \n\n        MiNK Therapeutics Inc. has announced updated clinical results from a study evaluating its allogeneic invariant natural killer T (allo-iNKT) cell therapy, agenT-797, both as a monotherapy and in combination with anti-PD-1 therapy. The data, presented at the Society for Immunotherapy of Cancer $(SITC)$ Annual Meeting 2025, involved patients with advanced solid tumors that were refractory to all approved treatments, including checkpoint inhibitors. The results demonstrated durable survival, deep and lasting responses, and evidence of immune reactivation, with a reported median overall survival of approximately 23 months when agenT-797 was combined with anti-PD-1 therapy. The therapy showed a favorable safety profile and consistent activity across tumor types, supporting the potential of iNKT cells as a new class of immune-restorative therapy. MiNK Therapeutics plans to advance agenT-797 into Phase 2 studies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571081-en) on November 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581886589","isCrawlerRequest":true}